Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
Guangzhou Wondfo Biotech C-A (300482 CH)
Watchlist
26
Analysis
Health Care
•
China
Guangzhou Wondfo Biotech Co.,Ltd. was founded in 1992. The company's line of business includes manufacturing of medical diagnostic tests. Guangzhou Wondfo Biotech serves customers around the world.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Ningbo Shuanglin Auto Parts
•
20 Jun 2025 10:10
Quiddity Leaderboard ChiNext & ChiNext 50 Dec25: ~US$600mn Collective One-Way Flows
We see US$366mn and US$231mn one-way flows for the ChiNext and ChiNext 50 rebalance events respectively. The ChiNext expected ADDs have strong...
Janaghan Jeyakumar, CFA
Follow
148 Views
Share
bearish
•
Lepu Medical Technology A
•
03 Jun 2025 13:00
Quiddity ChiNext/ChiNext 50 Jun25 Results: 23/26 Changes Correct Despite Methodology Change
We got 23 out of the 26 confirmed changes correct despite a last-minute change in methodology. We got all of the confirmed DELs correct. We had one...
Janaghan Jeyakumar, CFA
Follow
257 Views
Share
bearish
•
Sonoscape Medical Corp
•
06 May 2025 06:15
Quiddity Leaderboard ChiNext & ChiNext 50 Jun25: Last-Minute Methodology Changes; Final Expectations
There have been some last-minute changes to the index methodology which are expected to become effective during the June 2025 index rebal event. We...
Janaghan Jeyakumar, CFA
Follow
359 Views
Share
bearish
•
Sonoscape Medical Corp
•
17 Apr 2025 09:50
Quiddity Leaderboard ChiNext & ChiNext 50 Jun25: Some New Expectations; Try Sector-Neutral Pairs
There could be roughly US$1.4bn in total one-way flows for ChiNext and ChiNext 50 during the June 2025 index rebalance event. Some expectations...
Janaghan Jeyakumar, CFA
Follow
661 Views
Share
bullish
•
Livzon Pharmaceutical Group In
•
18 Aug 2024 02:59
China Healthcare Weekly (Aug.18)- COVID Is Here, BIOSECURE Act Update, Livzon Deserves More Patience
COVID is coming again. So investors can focus on related stocks. US companies leaving Chinese partners due to BIOSECURE Act. Livzon is still worth...
Xinyao (Criss) Wang
Follow
348 Views
Share
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.5
x